Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway

18 Jan 2019

Abstract excerpt

BACKGROUND: MYCN amplification or N-Myc overexpression is found in approximately 40% NEPC and up to 20% CRPC patients. N-Myc has been demonstrated to drive disease progression and hormonal therapeutic resistance of NEPC/CRPC. Here, we aim to identify the molecular mechanisms underlying the N-Myc-driven therapeutic resistance and provide new therapeutic targets for those N-Myc overexpressed NEPC/CRPC. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to MicroRNA in disease regulation
Share to Prostate Cancer Treatment and Research
Share to S100 Proteins and Annexins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30657058
DOI: 10.1186/s12943-019-0941-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathwayPMID 30657058Read ↗

Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate CancerSemantic proximity Read ↗

A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancerSemantic proximity Read ↗

Targeting the KDM4B–AR–c‐Myc axis promotes sensitivity to androgen receptor‐targeted therapy in advanced prostate cancerSemantic proximity Read ↗

A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancerSemantic proximity Read ↗

A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancerSemantic proximity Read ↗

A kinome-wide CRISPR screen identifies CK1α as a novel target to overcome enzalutamide resistance of prostate cancerSemantic proximity Read ↗

A MYC Family Switch: L-MYC Drives and Maintains Neuroendocrine Lineage Programs in Prostate CancerSemantic proximity Read ↗

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug TargetsSemantic proximity Read ↗

N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial CellsSemantic proximity Read ↗

Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.Semantic proximity Read ↗

LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a/RREB1 positive feedback loop and a ceRNA networkSemantic proximity Read ↗

KDM4A promotes the progression of neuroendocrine prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.